Join to View Full Profile
795 El Camino RealPalo Alto, CA 94301
Phone+1 650-853-2917
Dr. Pimienta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Pimienta is a Gastroenterology specialist based in Palo Alto, CA. He completed his Internal Medicine residency at the University of Southern California/Los Angeles General Medical Center in 2022, following his graduation from the University of California San Diego School of Medicine in 2019. Dr. Pimienta is currently a GI Fellow at Stanford Health Care. His research publications include studies on alcoholic pancreatitis, alcohol-associated hepatitis, alcohol use disorder, and inflammatory bowel disease. His work on naltrexone for alcohol use disorder has been notably cited 27 times in Hepatology Communications.
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2019 - 2022
University of California San Diego School of MedicineClass of 2019
Certifications & Licensure
CA State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 3 citationsEthanol inhibits pancreatic acinar cell autophagy through upregulation of ATG4B, mediating pathological responses of alcoholic pancreatitis.Olga A Mareninova, Sophie R Gretler, Grace E Lee, Michael Pimienta, Yueqiu Qin
American Journal of Physiology. Gastrointestinal and Liver Physiology. 2023-09-01 - 2 citationsProspective clinical trials and novel therapies in the medical management of severe alcohol-associated hepatitis.Michael Pimienta, Christine Tien, Norah A Terrault
Clinical Liver Disease. 2022-12-01 - 30 citationsNaltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.Divya Ayyala, Thomas Bottyan, Christine Tien, Michael Pimienta, Jennie Yoo
Hepatology Communications. 2022-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
